Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,911,214

« Back to Dashboard
Patent 6,911,214 protects KALETRA and is included in one NDA. There have been two Paragraph IV challenges on Kaletra. There are six tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for KALETRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 6,911,214

Title: Flavoring systems for pharmaceutical compositions and methods of making such compositions
Abstract:A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof. Pharmaceutical compositions of the invention include a flavoring system of the invention, a solvent system, and at least one pharmaceutically active agent, such as lopinavir or derivatives thereof, ritonavir or derivatives thereof, or mixtures thereof. Methods for making such liquid pharmaceutical compositions are also disclosed.
Inventor(s): Alani; Laman (Morris Plains, NJ), Gauwitz; Donald P. (McHenry, IL), Kaul; Dilip (Bridgewater, NJ), Lipari; John M. (Racine, WI), Ghosh; Soumojeet (Lindenhurst, IL), Marsh; Kennan C. (Lake Forest, IL), Whelan; Richard H. (Norfolk, MA), Petrossian; Vanik D. (Waban, MA)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:09/946,085
Patent Claim Types:
see list of patent claims
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 11th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
lopinavir; ritonavir
SOLUTION;ORAL021251-001Sep 15, 2000RXYes6,911,214*PEDMay 28, 2022Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.